SG11201708360TA - Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same - Google Patents
Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the sameInfo
- Publication number
- SG11201708360TA SG11201708360TA SG11201708360TA SG11201708360TA SG11201708360TA SG 11201708360T A SG11201708360T A SG 11201708360TA SG 11201708360T A SG11201708360T A SG 11201708360TA SG 11201708360T A SG11201708360T A SG 11201708360TA SG 11201708360T A SG11201708360T A SG 11201708360TA
- Authority
- SG
- Singapore
- Prior art keywords
- mesothelin
- fusions
- methods
- same
- growth factor
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146559P | 2015-04-13 | 2015-04-13 | |
| US201562243397P | 2015-10-19 | 2015-10-19 | |
| PCT/US2016/027136 WO2016168198A1 (en) | 2015-04-13 | 2016-04-12 | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708360TA true SG11201708360TA (en) | 2017-11-29 |
Family
ID=55809232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708360TA SG11201708360TA (en) | 2015-04-13 | 2016-04-12 | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10105427B2 (en) |
| EP (1) | EP3283509A1 (en) |
| JP (1) | JP6782253B2 (en) |
| KR (1) | KR20180002640A (en) |
| CN (1) | CN107750256A (en) |
| AU (1) | AU2016247887A1 (en) |
| BR (1) | BR112017022076A2 (en) |
| CA (1) | CA2982533A1 (en) |
| CO (1) | CO2017011431A2 (en) |
| CR (1) | CR20170507A (en) |
| EA (1) | EA201792274A1 (en) |
| EC (1) | ECSP17075380A (en) |
| HK (2) | HK1250730A1 (en) |
| IL (1) | IL254957A0 (en) |
| MA (1) | MA44379A (en) |
| MX (1) | MX2017013174A (en) |
| PH (1) | PH12017502080A1 (en) |
| SG (1) | SG11201708360TA (en) |
| SV (1) | SV2017005545A (en) |
| TW (1) | TW201710285A (en) |
| UY (1) | UY36616A (en) |
| WO (1) | WO2016168198A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3283509A1 (en) | 2015-04-13 | 2018-02-21 | Aduro Biotech, Inc. | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
| WO2016168214A2 (en) | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Immunogenic fusion proteins for the treatment of cancer |
| AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
| AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
| JP2021503897A (en) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | Reduced junction epitope presentation for nascent antigens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| WO2001072329A1 (en) | 2000-03-29 | 2001-10-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| JP4620808B2 (en) | 1994-11-28 | 2011-01-26 | トーマス・ジェファーソン・ユニバーシティ | Reagents and methods targeting mutant epidermal growth factor receptor |
| US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| AU2003265556A1 (en) | 2002-08-20 | 2004-03-11 | Millenium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| WO2004110481A2 (en) | 2003-02-06 | 2004-12-23 | Cerus Corporation | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
| EP1592442A2 (en) | 2003-02-06 | 2005-11-09 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
| US20050118186A1 (en) | 2003-06-17 | 2005-06-02 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
| PT1991263E (en) * | 2006-03-01 | 2015-03-03 | Aduro Biotech | Engineered listeria and methods of use thereof |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| CA2818353A1 (en) * | 2010-11-17 | 2012-05-24 | Aduro Biotech | Methods and compositions for inducing an immune response to egfrviii |
| KR102160322B1 (en) * | 2012-12-27 | 2020-09-25 | 아두로 바이오테크, 인코포레이티드 | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| CN104211814A (en) | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | Composition for target membrane protein depletion |
| WO2016168214A2 (en) | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Immunogenic fusion proteins for the treatment of cancer |
| EP3283509A1 (en) | 2015-04-13 | 2018-02-21 | Aduro Biotech, Inc. | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
-
2016
- 2016-04-12 EP EP16718812.7A patent/EP3283509A1/en not_active Withdrawn
- 2016-04-12 AU AU2016247887A patent/AU2016247887A1/en not_active Abandoned
- 2016-04-12 BR BR112017022076-8A patent/BR112017022076A2/en not_active Application Discontinuation
- 2016-04-12 US US15/097,178 patent/US10105427B2/en not_active Expired - Fee Related
- 2016-04-12 WO PCT/US2016/027136 patent/WO2016168198A1/en active Application Filing
- 2016-04-12 KR KR1020177031486A patent/KR20180002640A/en unknown
- 2016-04-12 SG SG11201708360TA patent/SG11201708360TA/en unknown
- 2016-04-12 JP JP2017554395A patent/JP6782253B2/en active Active
- 2016-04-12 CA CA2982533A patent/CA2982533A1/en not_active Abandoned
- 2016-04-12 CR CR20170507A patent/CR20170507A/en unknown
- 2016-04-12 EA EA201792274A patent/EA201792274A1/en unknown
- 2016-04-12 MA MA044379A patent/MA44379A/en unknown
- 2016-04-12 TW TW105111337A patent/TW201710285A/en unknown
- 2016-04-12 MX MX2017013174A patent/MX2017013174A/en unknown
- 2016-04-12 CN CN201680028967.8A patent/CN107750256A/en active Pending
- 2016-04-12 UY UY0001036616A patent/UY36616A/en not_active Application Discontinuation
-
2017
- 2017-10-09 IL IL254957A patent/IL254957A0/en unknown
- 2017-10-13 SV SV2017005545A patent/SV2017005545A/en unknown
- 2017-11-07 CO CONC2017/0011431A patent/CO2017011431A2/en unknown
- 2017-11-13 EC ECIEPI201775380A patent/ECSP17075380A/en unknown
- 2017-11-16 PH PH12017502080A patent/PH12017502080A1/en unknown
-
2018
- 2018-08-06 HK HK18110071.1A patent/HK1250730A1/en unknown
- 2018-08-10 HK HK18110280.8A patent/HK1250992A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2017011431A2 (en) | 2018-01-16 |
| MX2017013174A (en) | 2018-04-11 |
| TW201710285A (en) | 2017-03-16 |
| BR112017022076A2 (en) | 2018-08-14 |
| US10105427B2 (en) | 2018-10-23 |
| EP3283509A1 (en) | 2018-02-21 |
| US20160346369A1 (en) | 2016-12-01 |
| WO2016168198A1 (en) | 2016-10-20 |
| HK1250730A1 (en) | 2019-01-11 |
| JP6782253B2 (en) | 2020-11-11 |
| ECSP17075380A (en) | 2018-02-28 |
| IL254957A0 (en) | 2017-12-31 |
| HK1250992A1 (en) | 2019-01-18 |
| AU2016247887A1 (en) | 2017-11-02 |
| CR20170507A (en) | 2018-02-13 |
| UY36616A (en) | 2016-10-31 |
| CA2982533A1 (en) | 2016-10-20 |
| EA201792274A1 (en) | 2018-02-28 |
| SV2017005545A (en) | 2018-05-11 |
| PH12017502080A1 (en) | 2018-05-07 |
| JP2018512166A (en) | 2018-05-17 |
| CN107750256A (en) | 2018-03-02 |
| MA44379A (en) | 2019-01-23 |
| KR20180002640A (en) | 2018-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259019A1 (en) | Anti-pd1 antibodies and methods of use | |
| IL275944B (en) | 2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| HK1258058A1 (en) | Anti-tigit antibodies and methods of use | |
| HK1252858A1 (en) | Anti-cll-1 antibodies and methods of use | |
| HK1247569A1 (en) | Anti-pvrig antibodies and methods of use | |
| LT3368571T (en) | Transforming growth factor-beta-responsive polypeptides and their methods for use | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| HK1243444A1 (en) | Methods of producing long acting ctp-modified growth hormone polypeptides | |
| IL246528B (en) | Fusion protein inhibiting angiogenesis or growth and use thereof | |
| SI3551209T1 (en) | Insulin-fc fusions and methods of use | |
| HK1250992A1 (en) | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same | |
| GB201519128D0 (en) | Solid forms and methods of preparing the same | |
| HK1248122A1 (en) | Anti-met antibodies and methods of use thereof | |
| PL3110447T3 (en) | Anti-egfr antibody and uses of same | |
| HK1258850A1 (en) | Anti-tpbg antibodies and methods of use | |
| ZA202002041B (en) | Epidermal growth factor receptor inhibitors |